GlassScriptPhysician profile
Chiemeka Onyima
NPI 1215460076
$2,570.24
in general payments reported to CMS, 2019-2025
12 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 94% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $543 · 2022: $395 · 2023: $198 · 2024: $368 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935 · Travel and Lodging: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.83 |
| Travel and Lodging | $698.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $679.72 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Curonix LLC | $523.70 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $403.49 | 2021-2024 | Senza |
| Globus Medical, INC. | $378.12 | 2025 | Senza |
| Abbott Laboratories | $160.34 | 2021-2022 | |
| Avanos Medical | $133.33 | 2022 | |
| Boston Scientific Corporation | $117.44 | 2022-2025 | Intracept |
| Heron Therapeutics, INC. | $69.07 | 2021 | |
| Pfizer INC. | $32.81 | 2021 | |
| Almatica Pharma LLC | $30.83 | 2021 | |
| Allergan, INC. | $23.02 | 2021 | |
| Edwards Lifesciences Corporation | $18.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chiemeka Onyima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.